Bernard Chaitman, MD

Bernard Chaitman, MD, is a Professor of Internal Medicine and Director of Cardiovascular Research at St. Louis University School of Medicine, Missouri. He is also the Director of Core ECG Laboratory. Dr. Chaitman has research interests in anti-anginal drug therapies including Ranolazine, Nicorandil, fasudil, and ivabradine, lipid lowering therapy including investigational LDL lowering and HDL elevating therapy, ECG and QT analysis for drug registration studies, cardiac event classification for large cardiovascular multi-center clinical trials, non-invasive stress testing and cardiac risk stratification, indications for coronary revascularization, NSAID risk in cardiac patients, exercise physiology and training, nutrition, coronary artery disease, and noninvasive cardiac risk stratification. He is one of the Principal Investigators in the world's largest clinical trial comparing coronary revascularization to medical therapy in diabetic subjects. Dr. Chaitman is board certified in Internal Medicine, Cardiovascular Diseases, and Echocardiography. He is a Fellow of American College of Cardiology and American Heart Association-Council on Clinical Cardiology, and has served as President of the St. Louis Greater Division of the American Heart Association from 1998 to 2000. Dr. Chaitman has served as the Chair for numerous Data and Safety Monitoring Boards and Cardiac Event Adjudication Committees for NIH and industry sponsored clinical trials. (This is me - Update Profile)